Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, Y. Lynn Wang

Mol Cancer Ther (2018) 17 (12): 2564–2574.

https://doi.org/10.1158/1535-7163.MCT-17-0789-ATR

Published: 03 December 2018

View article titled, XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Includes: Supplementary data

Journal Articles

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi

Mol Cancer Ther (2017) 16 (1): 76–87.

https://doi.org/10.1158/1535-7163.MCT-16-0205

Published: 05 January 2017

View article titled, Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Includes: Supplementary data

Journal Articles

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

Shaun Rosebeck, Mattina M. Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P. Maxwell, Stephanie J. Kraftson, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej J. Jakubowiak

Mol Cancer Ther (2016) 15 (1): 60–71.

https://doi.org/10.1158/1535-7163.MCT-15-0488

Published: 07 January 2016

View article titled, Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

Includes: Supplementary data

Journal Articles

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Rachel A. Altura

Mol Cancer Ther (2014) 13 (3): 675–686.

https://doi.org/10.1158/1535-7163.MCT-13-0416

Published: 09 March 2014

View article titled, XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

William Senapedis, Marsha Crochiere, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Jean-Richard Saint-Martin, Ori Kalid, Sharon Shechter, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Eran Shacham, Sharon Tamir, Dilara McCauley, Erkan Baloglu, Michael Kauffman, Sharon Shacham, Yosef Landesman

Mol Cancer Ther (2013) 12 (11_Supplement): B198.

https://doi.org/10.1158/1535-7163.TARG-13-B198

Published: 01 November 2013

View article titled, Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

Journal Articles

Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Joshua Marcus, Yosef Landesman, Sharon Shacham, James Orth

Mol Cancer Ther (2013) 12 (11_Supplement): C49.

https://doi.org/10.1158/1535-7163.TARG-13-C49

Published: 01 November 2013

View article titled, Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Journal Articles

Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

Marsha L. Crochiere, Trinayan Kashyap, Jean-Richard Saint-Martin, Sharon Shechter, Ori Kalid, Eran Shacham, William Senapedis, Boris Klebanov, Sharon Tamir, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Erkan Baloglu, Dilara McCauley, Michael Kauffman, Sharon Shacham, Yosef Landesman

Mol Cancer Ther (2013) 12 (11_Supplement): A188.

https://doi.org/10.1158/1535-7163.TARG-13-A188

Published: 01 November 2013

View article titled, Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

Journal Articles

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack

Mol Cancer Ther (2013) 12 (7): 1171–1179.

https://doi.org/10.1158/1535-7163.MCT-12-1171

Published: 07 July 2013

View article titled, CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Includes: Supplementary data

NARROW

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

Abstract C49: Using single cell fluorescent cell cycle reporters to study mechanisms of action of selective inhibitors of nuclear export (SINE).

Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only